<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ozempic vs Wegovy: Same Drug, Different Uses</title>
    <meta name="description" content="Ozempic and Wegovy are both semaglutide but with different FDA approvals, doses, and insurance coverage. Learn the key differences and which is right for you.">
    <link rel="canonical" href="https://ozempic.md/ozempic-vs-wegovy">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ozempic.md/ozempic-vs-wegovy">
    <meta property="og:title" content="Ozempic vs Wegovy: Same Drug, Different Uses">
    <meta property="og:description" content="Both are semaglutide by Novo Nordisk, but with different FDA approvals, doses, and insurance coverage. Key differences explained.">
    <meta property="og:site_name" content="ozempic.md">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="ai-content" content="allowed">
    <meta name="ai-topic" content="ozempic vs wegovy, semaglutide, weight loss, diabetes, FDA approval">

    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "MedicalWebPage",
          "@id": "https://ozempic.md/ozempic-vs-wegovy#webpage",
          "name": "Ozempic vs Wegovy: Same Drug, Different Uses",
          "url": "https://ozempic.md/ozempic-vs-wegovy",
          "isPartOf": {"@id": "https://ozempic.md/#website"},
          "lastReviewed": "2026-02-01",
          "reviewedBy": {"@type": "Person", "name": "Dr. Agustin Arrieta", "jobTitle": "MD"}
        },
        {
          "@type": "FAQPage",
          "@id": "https://ozempic.md/ozempic-vs-wegovy#faq",
          "mainEntity": [
            {
              "@type": "Question",
              "name": "Are Ozempic and Wegovy the same drug?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Yes, both contain the same active ingredient — semaglutide — and are manufactured by Novo Nordisk. The key differences are FDA-approved indications (Ozempic for type 2 diabetes, Wegovy for chronic weight management), maximum dose (Ozempic 2 mg, Wegovy 2.4 mg), and insurance coverage pathways."
              }
            },
            {
              "@type": "Question",
              "name": "Why is Wegovy more effective for weight loss than Ozempic?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Wegovy's maximum dose (2.4 mg) is higher than Ozempic's maximum (2 mg), resulting in greater appetite suppression and weight loss. In the STEP 1 trial, Wegovy 2.4 mg produced average weight loss of 14.9% of body weight (~34 lbs) over 68 weeks, compared to 12-14 lbs with Ozempic at its diabetes doses."
              }
            },
            {
              "@type": "Question",
              "name": "Can I use Ozempic for weight loss instead of Wegovy?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Ozempic is not FDA-approved for weight loss, but doctors can prescribe it off-label. Some patients and doctors choose Ozempic because it may be easier to get insurance coverage (under a diabetes indication) or because Wegovy has had supply shortages. However, you won't reach the 2.4 mg dose that's specifically studied for weight loss."
              }
            },
            {
              "@type": "Question",
              "name": "Does insurance cover Wegovy?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Insurance coverage for Wegovy varies significantly. Many commercial plans cover it with prior authorization, but some exclude weight management drugs entirely. Medicare Part D generally does not cover weight loss medications, though this is changing with recent legislation. Ozempic often has broader coverage because it's classified as a diabetes drug."
              }
            },
            {
              "@type": "Question",
              "name": "Can I take Ozempic and Wegovy together?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "No. Ozempic and Wegovy contain the same active ingredient (semaglutide), so taking both would be a double dose. You should only take one semaglutide product at a time."
              }
            },
            {
              "@type": "Question",
              "name": "Is Wegovy more expensive than Ozempic?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "At retail, Wegovy is more expensive (~$1,300-1,400/month vs ~$900-1,000/month for Ozempic). However, actual out-of-pocket cost depends on insurance coverage. Some patients pay less for Wegovy if their plan covers weight management but not off-label Ozempic use for weight loss."
              }
            }
          ]
        }
      ]
    }
    </script>

    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root { --bg-primary: #ffffff; --bg-secondary: #f8fafc; --bg-tertiary: #f1f5f9; --text-primary: #0f172a; --text-secondary: #475569; --text-muted: #94a3b8; --accent: #0d9488; --accent-dark: #0f766e; --accent-light: #ccfbf1; --border: #e2e8f0; --font-display: 'Source Serif 4', Georgia, serif; --font-body: 'Inter', -apple-system, sans-serif; }
        html { scroll-behavior: smooth; } * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.7; font-size: 16px; }
        header { position: fixed; top: 0; left: 0; right: 0; z-index: 100; background: rgba(255,255,255,0.95); backdrop-filter: blur(10px); border-bottom: 1px solid var(--border); }
        .header-inner { max-width: 1100px; margin: 0 auto; padding: 16px 24px; display: flex; justify-content: space-between; align-items: center; }
        .logo { font-family: var(--font-display); font-size: 22px; font-weight: 600; color: var(--text-primary); text-decoration: none; } .logo span { color: var(--accent); }
        nav { display: flex; gap: 32px; } nav a { color: var(--text-secondary); text-decoration: none; font-size: 14px; font-weight: 500; } nav a:hover { color: var(--accent); }
        .article-hero { padding: 120px 24px 48px; max-width: 720px; margin: 0 auto; }
        .breadcrumb { font-size: 13px; color: var(--text-muted); margin-bottom: 16px; } .breadcrumb a { color: var(--accent); text-decoration: none; }
        .article-hero h1 { font-family: var(--font-display); font-size: clamp(32px, 5vw, 44px); font-weight: 700; line-height: 1.2; margin-bottom: 16px; }
        .article-meta { display: flex; flex-wrap: wrap; gap: 16px; align-items: center; font-size: 13px; color: var(--text-muted); }
        .review-badge { display: inline-flex; align-items: center; gap: 6px; background: var(--accent-light); color: var(--accent-dark); padding: 4px 12px; border-radius: 100px; font-size: 12px; font-weight: 600; }
        main { max-width: 720px; margin: 0 auto; padding: 0 24px 64px; }
        .section { margin-bottom: 48px; } .section-label { font-size: 12px; font-weight: 600; color: var(--accent); text-transform: uppercase; letter-spacing: 1px; margin-bottom: 12px; }
        h2 { font-family: var(--font-display); font-size: 28px; font-weight: 700; margin-bottom: 16px; }
        h3 { font-family: var(--font-display); font-size: 22px; font-weight: 600; margin-bottom: 12px; margin-top: 32px; }
        main p { font-size: 17px; color: var(--text-secondary); margin-bottom: 16px; line-height: 1.8; }
        main ul, main ol { margin: 0 0 16px 24px; color: var(--text-secondary); font-size: 17px; line-height: 1.8; } main li { margin-bottom: 8px; }
        .info-box { background: var(--accent-light); border: 1px solid #99f6e4; border-left: 4px solid var(--accent); border-radius: 8px; padding: 20px; margin: 24px 0; }
        .info-box h4 { font-size: 16px; font-weight: 600; margin-bottom: 8px; color: var(--accent-dark); }
        .info-box p { font-size: 15px; color: var(--accent-dark); margin-bottom: 0; }
        .comparison-table { width: 100%; border-collapse: collapse; margin: 24px 0; border: 1px solid var(--border); border-radius: 8px; overflow: hidden; }
        .comparison-table thead { background: var(--bg-secondary); }
        .comparison-table th { padding: 12px 16px; text-align: left; font-size: 13px; font-weight: 600; border-bottom: 1px solid var(--border); }
        .comparison-table td { padding: 12px 16px; font-size: 14px; color: var(--text-secondary); border-bottom: 1px solid var(--border); }
        .comparison-table tr:last-child td { border-bottom: none; }
        .faq-section { background: var(--bg-secondary); border-radius: 12px; padding: 32px; margin: 48px 0; }
        .faq-section h2 { font-size: 24px; margin-bottom: 24px; }
        .faq-item { border-bottom: 1px solid var(--border); padding: 16px 0; } .faq-item:last-child { border-bottom: none; }
        .faq-question { font-weight: 600; font-size: 16px; margin-bottom: 8px; } .faq-answer { font-size: 15px; color: var(--text-secondary); line-height: 1.7; }
        .sources { margin-top: 48px; padding-top: 32px; border-top: 1px solid var(--border); }
        .sources h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .sources ol { font-size: 14px; color: var(--text-muted); line-height: 1.8; } .sources a { color: var(--accent); text-decoration: none; }
        .related-articles { margin-top: 48px; padding: 32px; background: var(--bg-secondary); border-radius: 12px; }
        .related-articles h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .related-articles a { display: block; color: var(--accent); text-decoration: none; font-size: 15px; margin-bottom: 8px; font-weight: 500; }
        footer { background: var(--bg-secondary); border-top: 1px solid var(--border); padding: 48px 24px; }
        .footer-inner { max-width: 1100px; margin: 0 auto; text-align: center; }
        .footer-inner p { font-size: 14px; color: var(--text-muted); margin-bottom: 8px; } .footer-inner a { color: var(--accent); text-decoration: none; }
        @media (max-width: 768px) { nav { display: none; } .article-hero { padding: 100px 16px 32px; } .article-hero h1 { font-size: 28px; } main { padding: 0 16px 48px; } .faq-section { padding: 20px; } .comparison-table th, .comparison-table td { padding: 8px 10px; font-size: 12px; } }
    </style>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="https://ozempic.md" class="logo">ozempic<span>.md</span></a>
            <nav>
                <a href="https://ozempic.md">Home</a>
                <a href="https://ozempic.md/how-ozempic-works">How It Works</a>
                <a href="https://ozempic.md/side-effects-long-term">Side Effects</a>
                <a href="https://ozempic.md/ozempic-cost">Cost</a>
            </nav>
        </div>
    </header>

    <div class="article-hero">
        <div class="breadcrumb"><a href="https://ozempic.md">Home</a> → Ozempic vs Wegovy</div>
        <h1>Ozempic vs Wegovy: Same Drug, Different Uses</h1>
        <div class="article-meta">
            <span class="review-badge">✓ Medically reviewed by Dr. Agustin Arrieta, MD</span>
            <span>Last updated: February 2026</span>
        </div>
    </div>

    <main>
        <div class="section">
            <p>Ozempic and Wegovy contain the exact same active ingredient — semaglutide — made by the same company (Novo Nordisk). Yet they have different FDA approvals, different doses, different prices, and very different insurance coverage. This confuses a lot of people, understandably.</p>
            <p>Here's what's actually going on, and what it means for you.</p>
        </div>

        <div class="section">
            <div class="section-label">Key Differences</div>
            <h2>Side-by-Side Comparison</h2>

            <table class="comparison-table">
                <thead>
                    <tr><th>Feature</th><th>Ozempic</th><th>Wegovy</th></tr>
                </thead>
                <tbody>
                    <tr><td><strong>Active ingredient</strong></td><td>Semaglutide</td><td>Semaglutide</td></tr>
                    <tr><td><strong>Manufacturer</strong></td><td>Novo Nordisk</td><td>Novo Nordisk</td></tr>
                    <tr><td><strong>FDA indication</strong></td><td>Type 2 diabetes + CV risk reduction</td><td>Chronic weight management</td></tr>
                    <tr><td><strong>Maximum dose</strong></td><td>2 mg/week</td><td>2.4 mg/week</td></tr>
                    <tr><td><strong>Dose escalation</strong></td><td>0.25 → 0.5 → 1 → 2 mg</td><td>0.25 → 0.5 → 1 → 1.7 → 2.4 mg</td></tr>
                    <tr><td><strong>Time to max dose</strong></td><td>~8–16 weeks</td><td>~16–20 weeks</td></tr>
                    <tr><td><strong>Eligibility</strong></td><td>Adults with type 2 diabetes</td><td>Adults with BMI ≥30, or ≥27 with weight-related condition</td></tr>
                    <tr><td><strong>Retail price</strong></td><td>~$900–1,000/month</td><td>~$1,300–1,400/month</td></tr>
                    <tr><td><strong>Delivery device</strong></td><td>Pre-filled pen</td><td>Pre-filled pen</td></tr>
                    <tr><td><strong>Approved year</strong></td><td>2017</td><td>2021</td></tr>
                    <tr><td><strong>CV outcomes data</strong></td><td>SUSTAIN 6 (26% MACE reduction)</td><td>SELECT trial (20% MACE reduction in obesity without diabetes)</td></tr>
                </tbody>
            </table>
        </div>

        <div class="section">
            <div class="section-label">Why Two Products?</div>
            <h2>The Regulatory and Business Story</h2>

            <p>Novo Nordisk developed semaglutide first for type 2 diabetes (Ozempic, approved 2017). During diabetes clinical trials, they observed significant weight loss as a "side effect." This led them to study higher doses specifically for weight management, resulting in Wegovy (approved 2021).</p>

            <p>Creating a separate product for weight management was strategic:</p>
            <ul>
                <li><strong>Regulatory:</strong> Different FDA indications require different clinical trial programs. The STEP trials specifically studied semaglutide 2.4 mg for weight loss in people with and without diabetes.</li>
                <li><strong>Insurance:</strong> Diabetes drugs and weight management drugs follow different coverage pathways. Having separate products allows doctors to prescribe the right one for the right indication.</li>
                <li><strong>Dosing:</strong> The 2.4 mg weight management dose was not studied in the diabetes program. The additional 1.7 mg step in Wegovy's titration allows a more gradual approach to the higher dose.</li>
            </ul>

            <div class="info-box">
                <h4>The Off-Label Reality</h4>
                <p>Many doctors prescribe Ozempic off-label for weight loss because it's cheaper and easier to get covered by insurance. This is legal and common, but it means the maximum dose you'll reach is 2 mg rather than 2.4 mg, and insurance may not cover it if they discover the off-label use.</p>
            </div>
        </div>

        <div class="section">
            <div class="section-label">Efficacy</div>
            <h2>Weight Loss: How Much More Does 2.4 mg Deliver?</h2>

            <p>The dose difference matters. Here's what the clinical trials show:</p>

            <table class="comparison-table">
                <thead>
                    <tr><th>Trial</th><th>Drug / Dose</th><th>Population</th><th>Avg. Weight Loss</th><th>Duration</th></tr>
                </thead>
                <tbody>
                    <tr><td>SUSTAIN 1-5</td><td>Ozempic 1 mg</td><td>Type 2 diabetes</td><td>8–14 lbs (3.5–6.4 kg)</td><td>30–56 weeks</td></tr>
                    <tr><td>SUSTAIN FORTE</td><td>Ozempic 2 mg</td><td>Type 2 diabetes</td><td>~14 lbs (6.4 kg)</td><td>40 weeks</td></tr>
                    <tr><td>STEP 1</td><td>Wegovy 2.4 mg</td><td>Overweight/obesity (no diabetes)</td><td>33.7 lbs (14.9%)</td><td>68 weeks</td></tr>
                    <tr><td>STEP 2</td><td>Wegovy 2.4 mg</td><td>Overweight/obesity + type 2 diabetes</td><td>21.6 lbs (9.6%)</td><td>68 weeks</td></tr>
                    <tr><td>STEP 3</td><td>Wegovy 2.4 mg + intensive behavioral therapy</td><td>Overweight/obesity (no diabetes)</td><td>35.5 lbs (16%)</td><td>68 weeks</td></tr>
                </tbody>
            </table>

            <p>The weight loss difference between Ozempic 1-2 mg and Wegovy 2.4 mg is substantial — roughly double to triple in some comparisons. The higher dose, combined with longer trial durations and a population specifically selected for weight management, accounts for much of this gap.</p>

            <h3>Blood Sugar Control</h3>
            <p>For patients with type 2 diabetes, both work well for A1C reduction. Ozempic at 1-2 mg reduces A1C by 1.2-1.8% on average. In STEP 2, Wegovy 2.4 mg reduced A1C by 1.6% in patients with diabetes. The blood sugar effects are similar at comparable doses — the extra 0.4 mg in Wegovy doesn't dramatically change the diabetes picture.</p>

            <h3>Cardiovascular Outcomes</h3>
            <p>Both now have cardiovascular data:</p>
            <ul>
                <li><strong>Ozempic (SUSTAIN 6):</strong> 26% reduction in MACE in type 2 diabetes patients with established CV disease</li>
                <li><strong>Wegovy (SELECT):</strong> 20% reduction in MACE in people with obesity but without diabetes — a groundbreaking result that expanded semaglutide's CV indication beyond diabetes</li>
            </ul>
        </div>

        <div class="section">
            <div class="section-label">Insurance</div>
            <h2>Coverage: The Practical Reality</h2>

            <p>This is often the deciding factor. Insurance coverage for these two products differs dramatically because of their indications:</p>

            <h3>Ozempic Coverage</h3>
            <ul>
                <li><strong>Commercial insurance:</strong> Broadly covered for type 2 diabetes. Most plans include it on formulary with varying copays.</li>
                <li><strong>Medicare Part D:</strong> Covered for diabetes indication. Copays vary by plan tier.</li>
                <li><strong>Off-label for weight loss:</strong> Insurance generally will not cover Ozempic if prescribed solely for weight loss. Some patients work around this with a concurrent diabetes diagnosis.</li>
                <li><strong>Savings card:</strong> Novo Nordisk offers a card that can reduce copays to as low as $25/month for up to 24 months (commercially insured patients only, not for government insurance).</li>
            </ul>

            <h3>Wegovy Coverage</h3>
            <ul>
                <li><strong>Commercial insurance:</strong> Increasingly covered, but many plans still exclude weight management drugs or require extensive prior authorization (documented BMI, failed diet attempts, etc.).</li>
                <li><strong>Medicare Part D:</strong> Historically did not cover weight loss drugs. The Treat and Reduce Obesity Act (under consideration in Congress) could change this. Some Medicare Advantage plans have begun covering Wegovy.</li>
                <li><strong>Employer plans:</strong> Coverage varies widely. Large employers are increasingly adding weight management drug coverage.</li>
                <li><strong>Savings card:</strong> Novo Nordisk offers a program for eligible patients, but it's often more restrictive than the Ozempic savings card.</li>
            </ul>

            <div class="info-box">
                <h4>Practical Tip</h4>
                <p>If you have type 2 diabetes and want weight loss, Ozempic is often the easier path to insurance coverage. If you don't have diabetes but qualify based on BMI, Wegovy is the appropriate prescription — but verify your insurance coverage before filling.</p>
            </div>
        </div>

        <div class="section">
            <div class="section-label">Side Effects</div>
            <h2>Safety Comparison</h2>

            <p>The side effect profiles are virtually identical because it's the same drug. GI side effects (nausea, vomiting, diarrhea) are the most common and are dose-dependent — meaning Wegovy's higher dose may produce slightly more GI symptoms, but the more gradual titration (5 steps vs 4) helps offset this.</p>

            <table class="comparison-table">
                <thead>
                    <tr><th>Side Effect</th><th>Ozempic (1-2 mg)</th><th>Wegovy (2.4 mg)</th></tr>
                </thead>
                <tbody>
                    <tr><td>Nausea</td><td>15–20%</td><td>44% (STEP 1)</td></tr>
                    <tr><td>Diarrhea</td><td>8–9%</td><td>30%</td></tr>
                    <tr><td>Vomiting</td><td>5–9%</td><td>25%</td></tr>
                    <tr><td>Constipation</td><td>3–5%</td><td>24%</td></tr>
                    <tr><td>Discontinuation due to AEs</td><td>4–5%</td><td>7%</td></tr>
                </tbody>
            </table>
            <p style="font-size: 13px; color: var(--text-muted);">Wegovy rates appear higher partly because STEP trials reported cumulative incidence over 68 weeks, while SUSTAIN trials reported over shorter periods. The actual experience at any given time point is more comparable.</p>

            <p>Both carry the same boxed warning for thyroid C-cell tumors and the same contraindications (MTC, MEN 2, hypersensitivity to semaglutide).</p>
        </div>

        <div class="section">
            <div class="section-label">Supply</div>
            <h2>Availability and Shortages</h2>

            <p>Wegovy has experienced significant supply constraints since its launch in 2021. Novo Nordisk has struggled to meet the explosive demand for the weight management indication. As of early 2026, supply has improved substantially, but intermittent shortages of specific dose strengths still occur.</p>

            <p>Ozempic supply has been more stable, though it has also experienced periodic shortages due to the high overall demand for semaglutide products. Some patients prescribed Wegovy have been switched to Ozempic during shortages (and vice versa) under medical supervision.</p>
        </div>

        <div class="section">
            <div class="section-label">Decision</div>
            <h2>Which Is Right for You?</h2>

            <p><strong>Ozempic is typically prescribed when:</strong></p>
            <ul>
                <li>You have type 2 diabetes (with or without wanting weight loss)</li>
                <li>Cardiovascular risk reduction is a goal</li>
                <li>Your insurance covers diabetes medications but not weight management drugs</li>
                <li>Wegovy is unavailable in your area</li>
            </ul>

            <p><strong>Wegovy is typically prescribed when:</strong></p>
            <ul>
                <li>Weight management is your primary goal (BMI ≥30, or ≥27 with a weight-related condition)</li>
                <li>You don't have type 2 diabetes</li>
                <li>You want the maximum studied dose for weight loss (2.4 mg)</li>
                <li>Your insurance covers weight management medications</li>
            </ul>
        </div>

        <div class="faq-section">
            <h2>Frequently Asked Questions</h2>
            <div class="faq-item">
                <div class="faq-question">Are Ozempic and Wegovy the same drug?</div>
                <div class="faq-answer">Yes — same active ingredient (semaglutide), same manufacturer (Novo Nordisk). Different FDA approvals, doses, and insurance pathways. Ozempic is for type 2 diabetes (max 2 mg), Wegovy is for weight management (max 2.4 mg).</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Why is Wegovy more effective for weight loss than Ozempic?</div>
                <div class="faq-answer">Wegovy's maximum dose is 2.4 mg vs Ozempic's 2 mg. In the STEP 1 trial, Wegovy 2.4 mg produced ~34 lbs average weight loss over 68 weeks, roughly double to triple what's seen with Ozempic at diabetes doses.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Can I use Ozempic for weight loss instead of Wegovy?</div>
                <div class="faq-answer">Doctors can prescribe Ozempic off-label for weight loss. It's cheaper and often easier to get covered. But you won't reach the 2.4 mg dose studied specifically for weight management, and insurance may not cover off-label use.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Does insurance cover Wegovy?</div>
                <div class="faq-answer">Coverage varies significantly. Many commercial plans cover it with prior authorization. Medicare Part D generally doesn't cover weight loss drugs (though this is changing). Ozempic typically has broader coverage as a diabetes medication.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Can I take Ozempic and Wegovy together?</div>
                <div class="faq-answer">No. Both contain semaglutide. Taking both would be a double dose. Use one or the other, never both simultaneously.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Is Wegovy more expensive than Ozempic?</div>
                <div class="faq-answer">Yes — Wegovy retails at ~$1,300-1,400/month vs ~$900-1,000/month for Ozempic. Actual out-of-pocket cost depends entirely on your insurance plan's formulary and coverage.</div>
            </div>
        </div>

        <div class="sources">
            <h3>Sources</h3>
            <ol>
                <li>Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." <em>N Engl J Med.</em> 2021;384:989-1002. <a href="https://doi.org/10.1056/NEJMoa2032183">doi:10.1056/NEJMoa2032183</a> (STEP 1)</li>
                <li>Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." <em>Lancet.</em> 2021;397(10278):971-984.</li>
                <li>Wadden TA, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3)." <em>JAMA.</em> 2021;325(14):1403-1413.</li>
                <li>Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." <em>N Engl J Med.</em> 2023;389(24):2221-2232. (SELECT)</li>
                <li>Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." <em>N Engl J Med.</em> 2016;375(19):1834-1844. (SUSTAIN 6)</li>
                <li>FDA. "Ozempic Prescribing Information." <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf">FDA Label</a></li>
                <li>FDA. "Wegovy Prescribing Information." <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf">FDA Label</a></li>
            </ol>
        </div>

        <div class="related-articles">
            <h3>Related Articles</h3>
            <a href="https://ozempic.md/ozempic-vs-mounjaro">Ozempic vs Mounjaro: Which Is Better for Weight Loss? →</a>
            <a href="https://ozempic.md/how-ozempic-works">How Ozempic Works for Weight Loss: Mechanism Explained →</a>
            <a href="https://ozempic.md/ozempic-cost">How Much Does Ozempic Cost? →</a>
            <a href="https://ozempic.md/what-happens-when-you-stop">What Happens When You Stop Taking Ozempic →</a>
            <a href="https://ozempic.md/side-effects-long-term">Ozempic Side Effects: What to Expect →</a>
        </div>
    </main>

    <footer>
        <div class="footer-inner">
            <p><a href="https://ozempic.md" class="logo" style="font-size:18px;">ozempic<span>.md</span></a></p>
            <p>Evidence-based information about Ozempic (semaglutide). Not medical advice. Always consult your healthcare provider.</p>
            <p>Part of the <a href="https://thrive.md">thrive.md</a> network. © 2026</p>
        </div>
    </footer>
</body>
</html>
